Auranofin and Sirolimus in Treating Participants With Ovarian Cancer

Recurrent Ovarian Carcinoma Clinical Trial

Official title:

Phase II Trial to Evaluate the Efficacy of Auranofin and Sirolimus in Serous Ovarian Cancer Patients With Recurrent Disease

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03456700
• Other study ID #: MC1761
• Secondary ID: NCI-2018-00321MC
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: March 30, 2018
• Est. completion date: June 30, 2024

Study information

• Verified date: March 2024
• Source: Mayo Clinic
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase II trial studies how well auranofin and sirolimus work in treating participants with ovarian cancer. Immunosuppressive therapy, such as auranofin and sirolimus, is used to decrease the body?s immune response and may increase blood cell count.

Description:

PRIMARY OBJECTIVES:

I. To estimate the overall tumor response rate (ORR, that is, complete response [CR] + partial response [PR]) of the combination of auranofin and sirolimus in the setting of metastatic serous ovarian cancer across all patients.

SECONDARY OBJECTIVES:

I. To estimate the overall tumor response rate (ORR, that is, complete response [CR] + partial response [PR]) of the combination of auranofin and sirolimus in the setting of metastatic serous ovarian cancer within patients that have overexpression of PKCiota.

II. To estimate progression-free survival, overall survival, and adverse events from the combination of auranofin and sirolimus.

CORRELATIVE OBJECTIVES:

I. To explore whether PKCiota-relevant biomarkers in serous ovarian cancer tumors are associated with treatment response patterns, such as ORR, progression free survival, and overall survival.

OUTLINE:

Participants receive auranofin orally (PO) once daily (QD) and sirolimus PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.

After completion of study treatment, participants are followed up every 6 months for 3 years.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 22
• Est. completion date: June 30, 2024
• Est. primary completion date: July 31, 2019
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1

• Ovarian, Fallopian Tube or Primary Peritoneal cancer of serous histology

• Incurable cancer

• Willingness to provide paraffin-embedded tissue blocks of ovarian cancer

• Measurable disease

• Obtained =< 14 days prior to registration: Absolute neutrophil count (ANC) >= 1500 uL

• Obtained =< 14 days prior to registration: Platelet (PLT) >= 100,000 uL

• Obtained =< 14 days prior to registration: Hemoglobin (Hgb) >= 9 g/dL

• Obtained =< 14 days prior to registration: Total bilirubin =< 1.5 x upper limit of normal (ULN) or direct bilirubin =< ULN

• Obtained =< 14 days prior to registration: Serum glutamic-oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) and serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 3 x ULN or SGOT (AST) and SGPT (ALT) =< 5 x ULN is acceptable if liver has tumor involvement

• Obtained =< 14 days prior to registration: Creatinine =< 1.5 x ULN

• Obtained =< 14 days prior to registration: Fasting serum glucose =< 1.5 x ULN

• Obtained =< 14 days prior to registration: Total cholesterol =< 1.5 x ULN

• Obtained =< 14 days prior to registration: Triglycerides =< 1.5 x ULN

• Life expectancy >= 12 weeks

Exclusion Criteria:

• Platinum-sensitive disease (exceptions allowed: patient has had a hypersensitivity reaction to platinum or the treating oncologist thinks that further platinum therapy is not in the patient?s best interest)

• Morbidities or concurrent major illness (for example, bowel obstruction or a second active malignancy) that, in the opinion of the treating healthcare provider, would make participation in the trial problematic

• Leptomeningeal disease or uncontrolled brain metastasis

• Failure to recover from acute, reversible effects of prior therapy regardless of interval since last treatment

• NOTE: Patients can have peripheral (sensory) neuropathy

• History of hypertriglyceridemia or hypercholesterolemia and currently on medication(s)

• Use of St. John?s wort =< 7 days prior to registration

• Unable to discontinue use of a strong CYP3A4 inhibitor

Related Conditions & MeSH terms

• Ovarian Serous Tumor
• Recurrent Ovarian Carcinoma

Intervention

Drug:
• Auranofin
Given PO

Other:
• Laboratory Biomarker Analysis
Correlative studies

Drug:
• Sirolimus
Given PO

Locations

Country	Name	City	State
United States	Mayo Clinic	Rochester	Minnesota

Sponsors (2)

Lead Sponsor	Collaborator
Mayo Clinic	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With a Confirmed Tumor Response (Partial Response [PR] or Complete Response [CR] at Least 4 Weeks Apart)	The outcome measure is the number of participants with a confirmed tumor response (partial response [PR] or complete response [CR] at least 4 weeks apart). PR and CR are defined using RECIST 1.1 criteria. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. CR: Disappearance of all target and non-target lesions and normalisation of tumour marker level. Any pathological lymph nodes must have reduction in short axis to <10 mm.	1 year 4 months
Secondary	Number of Participants With a Confirmed Tumor Response (PR or CR at Least 4 Weeks Apart) in the Subset of Participants That Have Over-expression of Protein Kinase C (PKC) Iota	The outcome measure is the number of participants with a confirmed tumor response (partial response [PR] or complete response [CR] at least 4 weeks apart) in the subset of participants that have overexpression of PKC iota. PR and CR are defined using RECIST 1.1 criteria. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. CR: Disappearance of all target and non-target lesions and normalisation of tumour marker level. Any pathological lymph nodes must have reduction in short axis to <10 mm.	1 year 4 months
Secondary	Progression-free Survival (PFS)	Progression-free survival (PFS) is defined as the time from registration to the first of either disease progression or death from any cause. Patients who receive the study drug, but then never return for an evaluation will be censored on their last follow-up date. PFS will be estimated using the method of Kaplan-Meier. Progression is defined using RECIST 1.1 criteria; Progression: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression), Unequivocal progression (see comments below) of existing non-target lesions. (Note: the appearance of one or more new lesions is also considered progression), or appearance of new malignant lesions.	1 year 4 months
Secondary	Overall Survival (OS)	Overall survival (OS) is defined as the time from registration to death from any cause. OS will be estimated using the method of Kaplan-Meier.	1 year 4 months
Secondary	Number of Participants Experiencing at Least One Grade 3 or Worse Adverse Event (AE)	The outcome measure is the number of participants experiencing at least one grade 3 or worse adverse event (AE).	1 year 4 months